Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

Healthcare Biotechnology
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Satellos Bioscience Inc Com > they need to publish q3 financials and probably a good news
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by 75020780on Nov 22, 2017 10:59am
76 Views
Post# 27011339

RE:they need to publish q3 financials and probably a good news

RE:they need to publish q3 financials and probably a good news My bet is either:

1. Results from Immunes testing which isn't due for a while I believe
or
2. Immune is putting in an offer to buy us out (since they will owe us a $30mil payment in first half 2018 when they begin P3 testing. And they could throw in an offer of $7-8mil right now ($0.08-$0.085 per share) and literally everyone would be on board.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities